Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis
Brief Summary: The purpose of this study is to assess the clinical and microbiological effectiveness of the moxifloxacin compared with the combination ciprofloxacin - metronidazole, when used as adjunctive therapy to scaling and root planning for the treatment of advanced chronic periodontitis.


Options:
A: Inclusion Criteria:

* under 30 years old and systemically healthy, with at least 20 teeth present. Be willing to participate in the study which is corroborated by signing the informed consent form.

Commit to attend post-therapeutic controls and stop drinking alcohol during the time of ingestion of antibiotics.

Exclusion Criteria:

* Subjects in whom are contraindicated or with hypersensitivity to quinolones - Subjects who have undergone periodontal, surgical or mechanical antibiotic therapy six months before the start of the study according to interrogation.

Women in pregnancy or lactation, corroborated with previous medical history and medical consultation.
B: Inclusion Criteria:

* 18 years of age and up
* clinical and radiographic signs of severe (CAL 5 mm or more) chronic periodontitis.
* at least 20 natural teeth in situ
* pocket probing depths (PPDs) of ≥ 5 mm at a minimum of eight tooth sites
* willingness to participate and to be available at all times required for participation
* over 30% of the teeth present must have a PPDs)≥ 4 mm and insertion loss ≥ 5 mm evaluated by an experienced periodontist
* informed consent signed by the patient

Exclusion Criteria:

* if they (or parents or siblings) show confirmed or assumed allergies or hyper-sensitive skin reactions against moxifloxacin, ciprofloxacin (or other quinolones as listed in the "summary of product characteristics, Version Juli 2005"), metronidazole (or other 5-nitroimidazoles and ingredients of Flagyl® 400mg as listed in the "summary of product characteristics, Version Juli 2007"), systemic diseases or conditions as listed in the above mentioned "summary of product characteristics"
* subjects who have undergone antibiotic therapy three months before the start of the study under interrogation
* have Down's syndrome
* known AIDS/HIV
* regularly take systemic medication affecting the periodontal conditions, e.g. phenytoin, nifedipine, and/or steroid drugs
* professional periodontal therapy during 6 months prior to baseline
* require antibiotic treatment for dental appointments
* are pregnant or breastfeeding
C: Inclusion Criteria:

* The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.
* Patients were included if they were between 18 and 35 years of age and otherwise healthy.

Exclusion Criteria:

* if the patients had any known systemic diseases or conditions that can/could influence the periodontal status (cancer, cardiovascular and respiratory diseases)
* history of hepatitis or HIV infection,
* immunosuppressive chemotherapy
* current pregnancy, planning a pregnancy or lactation
* requirement for antibiotic prophylaxis
* oral diseases other than GAgP, ongoing orthodontic therapy
* a history of antibiotic therapy or periodontal treatment within the preceding six months.
* Subjects were excluded if they had known allergies to quinolones or penicillin or metronidazole
* Not willing to participate to the study.
* Not accept to sign written informed consent
D: Inclusion Criteria:

* Subjects must be 20 years of age or older
* Have at least 18 natural teeth
* Four or more clinical attachment level(CAL) ≥ 3mm
* Four or more periodontal pockets with a probing depth (PD) ≥ 4mm
* Have Bleeding on probing
* Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

* Forbidden History of Panax Notoginseng and Rehmanniae Radix Preparata
* Hypersensitivity of Doxycycline
* Hypersensitivity of Zea mays L. extract
* Critical diseases such as HIV previous three years
* Patients with mental retardation and dementia
* Systemic diseases such as diabetes and hypertension
* Patients who take Anticoagulants or Antiplatelet Agents
* Patients who have malignant tumor
* Smoker
* Continually use for 2weeks of phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month
* Patients who need malignant tumor
* Patients who received periodontal treatment within the last 6 months
* Pregnant or lactating females

Answer: B